



# IOWA MEDICAID CLINICAL ADVISORY COMMITTEE ACTIVITY SUMMARY SFY24

OCTOBER 2024

## Table of Contents

<a href="#"><u>Medicaid Clinical Advisory Committee Background And Objectives</u></a> .....	2
<a href="#"><u>Committee Members</u></a> .....	3
<a href="#"><u>Review of Iowa Medicaid Clinical Criteria</u></a> .....	4

# Medicaid Clinical Advisory Committee Background and Objectives

The establishment and requirements of the Iowa Medicaid Clinical Advisory Committee (CAC) are contained in House File 841 and the Medicaid CAC was initiated in 2006. The purpose of the Medicaid CAC is to increase the efficiency, quality, and effectiveness of the Iowa Medicaid healthcare system. The CAC provides a process for physicians and other healthcare providers to promote quality care, member safety, and fiscal responsibility through a discussion of Medicaid benefits and healthcare services criteria.

The Medicaid CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decisions for the Iowa Medicaid program. This annual report summarizes the recommendations made by the Medicaid CAC and those adopted by rule.

The Medicaid CAC performs:

- Technology and therapeutics review for advanced therapy and new technology.
- Administrative support through its review and recommendations regarding policy issues.
- Criteria review with recommendations for changes.

The Medicaid CAC meetings are subject to the open committee rules in Chapter 21 of the Iowa Administrative Code. All meetings are publicly announced on the HHS website a minimum of 10 days prior to the scheduled date and time. All meeting agendas, minutes, a summary of Medicaid CAC responsibilities, and Medicaid CAC questions and answers are posted on the HHS website.

Appointments are for 3 years, and each member may be reappointed for one additional 3-year term.

The Iowa Medicaid Quality Improvement Organization (QIO) unit is responsible for the administration of the Medicaid CAC. The Iowa Medicaid medical director, Dr. William (Bill) Jagiello, chairs the Medicaid CAC. The chair of the Medicaid CAC may only vote in the situation that the committee has a tie vote.

Else Umbreit, PharmD, is part of the QIO unit and is experienced working in the managed care setting. She applies her knowledge in the review and development of criteria for physician administered medications, as well as with new code reviews.

The Medicaid managed care organizations (MCOs) send clinical representation, typically an MCO medical director, to the Medicaid CAC meetings. The MCO medical directors are not voting members of the Medicaid CAC; however, they contribute to clinical criteria discussions to ensure criteria are implemented consistently.

The Medicaid CAC evaluates the clinical aspects of Iowa Medicaid coverage policies and medical management strategies to maximize both quality healthcare and cost effectiveness. The Medicaid CAC provides recommendations in the early stages of policy development and change, through collaboration with the Policy unit, which enhances buy-in from the Medicaid provider network.

## Committee Members

### **Clarice Blanchard PA-C, MMS**

Clarice Blanchard graduated from Luther College in Decorah, Iowa, with a Bachelor of Arts in Biology and Psychology in 1996. She then received her physician assistant training at St. Louis University in St. Louis, Missouri, graduating in 1999. Clarice has practiced in family medicine and emergency medicine at Madison County Healthcare System in Winterset, Iowa, since 2001.

### **Dana Danley, MD**

Dr. Danley graduated from the University of Iowa College of Medicine, Iowa City, Iowa, in 1998. She completed her post-graduate training in family practice at Broadlawns Medical Center in 2001 and is board-certified in Family Practice. Dr. Danley is an active educator in medical student education as an Adjunct Assistant Family Medicine faculty at Des Moines University and an Adjunct Clinical Associate Professor at the Carver College of Medicine. Dr. Danley also is a faculty member of the Broadlawns Medical Center Family Medicine Residency and has received several awards for teaching. She currently practices at Broadlawns Medical Clinic in Des Moines, Iowa.

### **Polly Ferguson, MD**

Dr. Ferguson graduated from the University of Iowa Carver College of Medicine in Iowa City, Iowa, in 1990. She completed a pediatric residency in 1993, a pediatric rheumatology and immunology fellowship in 1996 and a post-doctoral research fellowship in 2000 at the University of Virginia in Charlottesville, Virginia. Dr. Ferguson joined the faculty at the University of Alabama at Birmingham in 2000 and subsequently took a faculty position at the University of Iowa in 2002 where she remains. She currently is a Professor of Pediatrics and Director of Pediatric Rheumatology, Allergy, and Immunology at the University of Iowa Stead Family Department of Pediatrics.

### **Alexandra K. Hubbell, DO**

Dr. Hubbell graduated from Des Moines University in 2007 and completed her residency at Iowa Lutheran Family Medicine Program in Des Moines, Iowa, in 2013. Dr. Hubbell is the Associate Program Director at the Iowa Lutheran Family Medicine Residency.

### **Kathleen Lange, MD**

Dr. Lange graduated from the University of Iowa College of Medicine in Iowa City, Iowa, in 1992. She completed her residency at Iowa Lutheran Hospital in Des Moines, Iowa, in 1997. She actively participates in several professional affiliations and memberships. Dr. Lange currently practices at Chariton Valley Medical Center in Centerville, Iowa, in family practice.

### **Stephen R. Mandler, DO**

Dr. Mandler is board certified in Adult, Child, and Adolescent Psychiatry. He did his Medical Internship at Oregon Health and Sciences University, and Residency and Fellowship at The Menninger Clinic. He is currently the Chief Medical Officer at Orchard Place. Orchard Place annually serves more than 10,000 children across Iowa from birth to age 22 through a wide variety of mental health services for children and young adults. Previously he served as Regional Medical Officer Psychiatrist, US Department of State, Foreign Service, and worked in Afghanistan, Mexico, and West Africa. He has served on the faculty of Oregon Health Sciences University and Portland State University's Graduate Program of Infant/Toddler Mental Health. Dr. Mandler is an appointed member of the Iowa Council for Early ACCESS.

**Dennis Zachary, MD**

Dr. Zachary graduated from the Mayo Medical School in Rochester, Minnesota in 1984. He completed his post-graduate training in family practice at North Memorial Branch at the University of Minnesota in 1987. He is board-certified in family practice, geriatric medicine, and sports medicine. He actively participates in several professional affiliations and memberships. He has been the recipient of numerous military honors. Dr. Zachary currently practices at Mercy South Medical Clinic in Des Moines, Iowa, in family practice.

**Chitravathi Yerrapareddy, MD**

Dr. Reddy graduated from Kurnool Medical College in May 1994. She completed her internship at Government General Hospital in April 1995. She is board-certified in Internal Medicine, Endocrinology, and American Board of Obesity Medicine. She actively participates in several professional affiliations and community services. Dr. Reddy currently practices at UnityPoint Clinic Diabetes & Endocrinology in Cedar Falls, Iowa.

**Diana Smith, DNP, ARNP, FNP-C**

Diana Smith graduated from Maryville University in St. Louis, Missouri in August 2022. She actively participates in several professional affiliations and memberships and has received several professional certifications. Diana Smith currently practices at Greene County Family Medicine/UnityPoint Clinic in Jefferson, Iowa, and at McCrary Rost Clinic/Stewart Memorial Community Hospital in Gowrie, Iowa and Lake City, Iowa.

**Geetanjali Sahu, MD**

Dr. Sahu completed her medical school at the Chhattisgarh Institute of Medical Sciences in India. She did her psychiatry residency at Maimonides Medical Center in Brooklyn, New York, followed by a child and adolescent psychiatry fellowship at the University of Texas at Houston, Texas. Dr. Sahu has earned regional and national accolades for her clinical and research work. Notably, the AACAP Pilot Research Award for Junior Faculty and Child and Adolescent Psychiatry Fellows and the American Association of Directors of Psychiatric Residency Training International Medical Graduate Fellowship Award. Dr. Sahu is ABPN board-certified in both adult psychiatry as well as child and adolescent psychiatry. She uses a knowledge of biological, psychological, and social factors in working with patients and families. Her clinical interests include childhood trauma, bipolar disorders, developmental disorders, school-based mental health, and family ecosystems. Dr. Sahu is invested in collaborating care with other caregivers as she truly believes it takes a village to raise a child. She currently practices at Broadlawns Outpatient Behavioral Health, Main Campus in Des Moines, Iowa.

## Review of Iowa Medicaid Clinical Criteria

A key function of the Medicaid CAC is to provide Iowa Medicaid with an annual review of the criteria utilized for physician-administered drugs and medical review. Using the wide range of expertise represented by the Medicaid CAC members, review of each established and new criteria considers standards of practice, the effect of treatment on quality of life, functional status, and other relevant aspects of the health of Medicaid members.

QIO Services also recruits specialists throughout Iowa to review the following specialized criteria annually:

- Bone marrow and/or peripheral blood stem cell transplant,
- Heart transplant,
- Liver transplant,
- Lung transplant,
- Pancreas transplant,
- Orthodontic procedures, and
- Periodontic procedures.

The table below and on the following pages lists the criteria reviewed by the Medicaid CAC during SFY24.

Criteria	Actioned
Abecma (idecabtagene vicleucel)	October 2023
Ablative Laser Treatment of Burns and Traumatic Scars	January 2024
Adakveo (crizanlizumab-tmca)	July 2023
Adstiladrin (nadofaragene firadenovec-vncg)	January 2024
Aduhelm (aducanumab)	October 2023
Amondys 45 (casimersen)	October 2023
Amvuttra (vutrisiran)	January 2024
Artificial Disc Replacement	July 2023
Artificial Disc Replacement	January 2024
Augmentative Communication Systems	April 2024
Autologous Chondrocyte Implantation	October 2023
Bariatric Surgery	January 2024
Bariatric Surgery	April 2024
Bavencio (avelumab)	October 2023
Blepharoplasty	April 2024
Bone Marrow/Peripheral Blood Stem Cell Transplant	April 2024
Botulinum Toxins	April 2024
Breyanzi (lisocabtagene maraleucel)	October 2023
Briumvi (ublituximab-xiyy)	October 2023
Carvykti (ciltacabtagene autoleucel)	October 2023
Ceiling Track Lifts and/or Electric Patient Lifts	January 2024
Children's Mental Health Level of Care	July 2023
Chromosomal Microarray Analysis	January 2024
Cochlear Implant	April 2024
Cochlear Implant Repair and Replacement	April 2024
Consumer-Directed Attendant Care	April 2024
Continuous Glucose Monitoring	October 2023
Continuous Glucose Monitoring	January 2024
Cranial Orthotics	January 2024
Crysvita (burosumab-twza)	July 2023
Crysvita (burosumab-twza)	April 2024
CT Colonography	January 2024

Criteria	Actioned
Custom Knee Orthotics	July 2023
Danyelza (naxitamab-ggqk)	October 2023
Darzalex and Darzalex Faspro (daratumumab; daratumumab and hyaluronidase-fihj)	October 2023
Elahere (mirvetuximab soravtansine-gynx)	October 2023
Elaprase (idursulfase)	April 2024
Elfabrio (pegunigalsidase alfa-iwxj)	April 2024
Enhertu (fam-trastuzumab deruxtecan-nxki)	January 2024
Enjaymo (sutimlimab-jome)	April 2024
Enteral Products and Supplies	July 2023
Environmental Modification-Adaptive Devices	January 2024
Exondys 51 (eteplirsen)	October 2023
Family Functional Therapy	October 2023
Fasenra (benralizumab)	July 2023
Fecal Microbiota Transplantation	January 2024
Fyarro (sirolimus protein-bound particles)	July 2023
Gait Trainer/ Stander	April 2024
Gene Expression Profiling for the Management of Breast Cancer	July 2023
Genetic Testing (excludes BRCA)	April 2024
Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1-BRCA2)	January 2024
Genetic Testing for Lynch Syndrome	July 2023
Habilitation Eligibility (Non-Financial)	July 2023
Heart Transplant	January 2024
High Frequency Chest Wall Oscillators	July 2023
Home and Vehicle Modification	January 2024
Imfinzi (durvalumab)	January 2024
Imjudo (tremelimumab-actl)	July 2023
Imjudo (tremelimumab-actl)	January 2024
Injectafer (ferric carboxymaltose)	January 2024
Intermediate Care Facility for Intellectual Disability Level of Care	January 2024
Jelmyto (mitomycin gel)	April 2024
Jemperli (dostarlimab-gxly)	July 2023
Kadcyla (ado-trastuzumab emtansine)	October 2023
Keytruda (pembrolizumab)	July 2023
Kimmtrak (tebentafusp-tebn)	January 2024
Korsuva (difelikefalin)	April 2024
Krystexxa (pegloticase)	July 2023
Krystexxa (pegloticase)	April 2024
Kymriah (tisagenlecleucel)	July 2023
Kymriah (tisagenlecleucel)	April 2024



Criteria	Actioned
Lamzede (velmanase alfa-tycv)	April 2024
Laser Linear Accelerator Based Stereotactic Radiosurgery	July 2023
Left Ventricular Assist Device	July 2023
Leqembi (lecanemab-irmb)	October 2023
Liver Transplant	January 2024
Lung Transplant	January 2024
Lunsumio (mosunetuzumab-axgb)	April 2024
Lutathera (lutetium Lu 177 dotatate)	January 2024
Luxturna (voretigene neparvovec-rzyl)	April 2024
Margenza (margetuximab-cmkb)	July 2023
Medical Day Care for Children	October 2023
Medical Foods	July 2023
Mobility Related Device Purchase	January 2024
Molecular Analysis for Targeted Therapy of Non-Small Cell Lung Cancer	July 2023
Molecular Analysis for Targeted Therapy of Non-Small Cell Lung Cancer	January 2024
Molecular Analysis for Targeted Therapy of Non-Small Cell Lung Cancer	April 2024
Monjuvi (tafasitamab-cxix)	July 2023
Multi-Systemic Therapy	October 2023
Myoelectric Prosthesis Upper Extremity	January 2024
Namenda (memantine) for Autism Spectrum Disorder	July 2023
Natalizumab Agents (Tysabri, Tyruko)	April 2024
Negative Pressure Wound Therapy	October 2023
Nexviazyme (avalglucosidase alfa-ngpt)	July 2023
Nexviazyme (avalglucosidase alfa-ngpt)	April 2024
Nipple Tattooing	January 2024
Non-Invasive Prenatal Testing for Aneuploidy Using Cell Free DNA	January 2024
Nursing Facility Level of Care	April 2024
Ocrevus (ocrelizumab)	April 2024
Opdualag (nivolumab and relatlimab-rmbw)	July 2023
Orphan Drug (Rare Disease)	January 2024
Orthodontic Procedures	January 2024
Padcev (enfortumab vedotin-efjv)	October 2023
Pancreas Transplant	January 2024
Panniculectomy	October 2023
Pediatric SNF Level of Care	April 2024
Percussors	October 2023
Periodontic Procedures	January 2024
Personal Care Services for Children	April 2024



Criteria	Actioned
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)	October 2023
Pluvicto (lutetium Lu 177 vipivotide tetraxetan)	April 2024
Pneumatic Compression Devices	July 2023
Power Seat Elevation for Power Wheelchairs	January 2024
Power Wheelchair Attendant Controls	January 2024
Pre-Vocational Services	April 2024
Private Duty Nursing for Children	April 2024
Psychiatric Medical Institution for Children Level of Care	April 2024
Qalsody (tofersen)	April 2024
Radicava (edaravone)	April 2024
Reduction Mammoplasty/Mastopexy	July 2023
ReliZORB (immobilized lipase) Cartridge	January 2024
Repetitive Transcranial Magnetic Stimulation	October 2023
Risk Reduction Mastectomy	July 2023
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn]	July 2023
Rystiggo (rozanolixizumab-noli)	April 2024
Safety Beds	April 2024
Sarclisa (isatuximab-irfc)	July 2023
Septoplasty/ Rhinoplasty	April 2024
Serum Iron Studies	April 2024
Shower/Commode Chair	April 2024
Skilled Level of Care	April 2024
Spinraza (nusinersen)	April 2024
Spravato (esketamine nasal spray)	April 2024
Strollers and Wheelchairs for Safety	July 2023
Tecartus (brexucabtagene autoleucel)	January 2024
Tecvayli (teclistamab-cqyv)	October 2023
Tepezza (teprotumumab-trbw)	April 2024
Testing for Hereditary Cancer Susceptibility Syndromes Using Multi-Gene Panels	January 2024
Trodelyv (sacituzumab govitecan-hziy)	July 2023
Tysabri (natalizumab govitecan-hziy) ( <i>archived</i> )	April 2024
Uplizna (inebilizumab-cdon)	July 2023
Vagus Nerve Stimulator	April 2024
Varicose Vein Treatment	January 2024
Viltepso (viltolarsen)	October 2023
Visual Aids and Vision Therapy	January 2024
Vitamin, Mineral, Amino Acid Supplements	January 2024
Vyepti (eptinezumab-jjmr)	January 2024
Vyondys 53 (golodirsen)	October 2023

Criteria	Actioned
Vyvgart and Vyvgart Hytrulo (efgartigimod alfa-fcab; efgartigimod alfa and hyaluronidase-qvfc)	January 2024
Wearable Automated External Defibrillator	July 2023
Wearable Automated External Defibrillator	October 2023
Whole Exome Sequencing-XomeDX	January 2024
Xenpozyme (olipudase alfa-rpcp)	January 2024
Yescarta (axicabtagene ciloleucel)	July 2023
Zolgensma (onasemnogene abeparvovec-xioi)	January 2024
Zulresso (brexanolone)	October 2023
Zynlonta (loncastuximab tesirine-lpyl)	July 2023
Zynyz (retifanlimab-dlwr)	January 2024
Zynyz (retifanlimab-dlwr)	April 2024